Overview
AstraZeneca is a global biopharmaceutical company headquartered in Cambridge, United Kingdom, that discovers, develops and commercialises prescription medicines in oncology, rare diseases and biopharmaceuticals, the latter covering cardiovascular, renal and metabolic disease and respiratory and immunology.[2] Forbes records sales of US$60.4bn, 11.8% above the prior-year figure, and profit of US$10.4bn, making it the largest British company in the list.[2] Its market value of US$282.1bn exceeds that of Merck & Co. and Pfizer, which both have higher sales. AstraZeneca employs 96,100 people according to the same dataset.[2] It moved from sixth to seventh place on the prior-year comparison only because Eli Lilly overtook it, and it remains slightly behind AbbVie on sales.[2]
AstraZeneca PLC strengths and limitations
Strengths
- Largest UK-headquartered company in the ranking
- Double-digit sales growth
- Diversified across oncology, rare disease and respiratory
Limitations
- Profit margin below Novartis and Roche
- Dollar figures depend on reporting currency
- Competition in oncology is intense
Appears in
AstraZeneca PLC peers and competitors
Companies ranked in the same lists as AstraZeneca PLC.
GSK plc
Takeda Pharmaceutical
Merck & Co.
Pfizer- AbbVie
Novartis
Bayer AG
Novo Nordisk
Sanofi- Bristol Myers Squibb
- Amgen
Shell plc
Is this your company?
Update the description, logo, image and link through the submission form. Editors review every change.